🔴 Intellia Therapeutics is trading 5.1% down today as safety concerns and dilution worries extend a multi-day slide

Intellia Therapeutics is trading at $12.62 (5.1% down) in after-hours trading, extending a sharp multi-day decline as investors weigh pipeline risks and funding needs.

• The stock remains under pressure from lingering safety concerns and clinical holds regarding its ATTR program, alongside previous workforce reductions and strategic restructuring.
• Ongoing dilution worries and insider selling linked to recent equity offerings continue to weigh on sentiment, prompting a risk-off reassessment of the company's pipeline.